U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06987916) titled 'Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma' on May 15.
Brief Summary: This is an open-label phase1 study to assess the safety and efficacy of U01(ssCART-19) cell therapy in the treatment of refractory or recurrent DLBCL
Study Start Date: April 22
Study Type: INTERVENTIONAL
Condition:
B Cell Non-Hodgkin&Amp;#39;s Lymphoma
Intervention:
DRUG: ssCART-19
autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene
Recruitment Status: RECRUITING
Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Information provided by...